- Home
- WLTH vs LTGO Comparison
WLTH vs LTGO Comparison
Compare WLTH & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WLTH | LTGO |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2025 | 2026 |
Fundamental Metrics
Financial Performance| Metric | WLTH | LTGO |
|---|---|---|
| Price | $10.37 | $16.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $12.11 | ★ $52.25 |
| AVG Volume (30 Days) | ★ 2.9M | 240.1K |
| Earning Date | 09-09-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $364,993,000.00 | N/A |
| Revenue This Year | $2.72 | N/A |
| Revenue Next Year | $17.23 | N/A |
| P/E Ratio | $56.06 | ★ N/A |
| Revenue Growth | ★ 18.17 | N/A |
| 52 Week Low | $7.20 | $16.19 |
| 52 Week High | $14.12 | $25.93 |
Technical Indicators
Market Signals| Indicator | WLTH | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 34.69 |
| Support Level | $10.22 | $16.19 |
| Resistance Level | $11.18 | $20.49 |
| Average True Range (ATR) | 0.46 | 1.68 |
| MACD | 0.00 | -0.67 |
| Stochastic Oscillator | 66.39 | 7.32 |
Price Performance
Historical ComparisonAbout WLTH Wealthfront Corporation Common Stock
Wealthfront Corp is a product-driven technology company that built a financial solutions platform for digital natives. The platform is designed to address the needs of the wealth builders within these generations. Its business model is designed to optimize for clients' success. The focus on delivering fully automated services results in being one of the lowest cost producers in each category in which participate. The group generates revenue from cash management and investment advisory products. Cash management revenue is earned from fees received for the delivery of cash management services, including the cash sweep program.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.